Cord Blood Amer Inc. (WKN: A0EAGC / CBAI) / OTCBB

Cord Blood America Inc. (CBAI.OB: 0.0054 +10.20%) shares jumped more than 10 percent after it announced a conference call to discuss its first quarter results and corporate developments. The call is scheduled for Thursday, May 21st at 11:00 a.m. Eastern Time. Many investors are bullish on this quarter’s results given the breadth of recent news announcements.

Quelle + Volltext: theotcinvestor.com/...otc-bb-and-pinksheets-market-movers-240/

Übersetzungshilfe: translate.google.de/translate_t#

0.0056
+0.0007 (14.29%)
Delayed:   3:35PM EDT    Open:  0.00    Mkt Cap:  6.26M    P/E:      -    Dividend:      -  
 High:  0.01    52Wk High:  0.03    F P/E:      -    Yield:      -  
 Low:  0.00    52Wk Low:  0.00    Beta:  -3.19    Shares:  1.12B  
 Volume:  54.63M    Avg Vol:      -    EPS:  -0.03    Inst. Own:  0%

biz.yahoo.com/e/090520/cbai.ob10-q.html

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.

There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. Cord Blood America, Inc., through its wholly owned subsidiaries, CorCell Companies Inc., and Cord Partners, Inc., markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive. Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.

Quelle + Volltext: www.baystreet.ca/users/newswire/viewarticle.aspx?id=27494

Übersetzungshilfe: translate.google.de/translate_t#

www.finanznachrichten.de/...strengthened-balance-sheet-008.htm

21.05.2009 14:07
Cord Blood America, Inc. Announces 2009 First Quarter Results / Company Reports Improved Operating Results, Strengthened Balance Sheet

SANTA MONICA, Calif., May 21 /PRNewswire-FirstCall/ -- Cord Blood America, (News) Inc. (BULLETIN BOARD: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today financial highlights for its 2009 first quarter for the period ended March 31, 2009.

Some of the highlights include:


-- Improved operating results. The Company reduced its loss from operations from $0.4 million in its 2008 first quarter to $0.3 million in the 2009 first quarter.

-- Increased gross margin. The Company increased gross margin from 45.0% in the 2008 first quarter to 52.5% in the 2009 first quarter due to a more favorable mix of business, including a significantly higher percentage of revenue coming from the sale of umbilical cord blood stem cell preservation services.

-- Strengthened balance sheet. Indebtedness under the Company's convertible debentures declined from $6.8 million one year ago to $5.6 million at the end of the 2009 first quarter. Current liabilities fell from $13.6 million to $12.4 million.

-- Strong growth in billings for Company's core business. Cord's billings in the three-month period ended March 31, 2009 was $1.2 million, compared to $1.0 million in the year earlier period as reflected in the Company's deferred revenue. Deferred revenue consists of payments for enrollment in the program and processing of umbilical cord blood by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

...(weiter siehe LINK)

Berlin  0,004 €  ebB* 0,00%   0,004 €  38.397  38.397  0,003 - 0,004  11:34:32

Zahlen des Unternehmen vom 21.05.09 zeigen eine klare Verbesserung. Weiterhin wird die neue US-Regierung wahrscheinlich das "Verbot" der Stammzellenforschung  aufheben. Sie bereits angekündigt, dafür große Summen zur Verfügung zu stellen. Das hat  e n o r m e  positive Auswirkung auf die Geschäfte des Unternehmens.   Sollte dies zutreffen wird der Aktienkurs explodieren!!

Danke im Voraus

wenn nicht die Anzahl der Aktien wäre. !10 Beschäftigte und Milliarden Aktien im Markt. Das gibt sicherlich merhrere Splits i.d. Zukunft.
Die werden wir wohl niemals bei 1,x sehen. Trotzdem: 100k gebunkert und die sehe ich mir 2012 wieder an.

Decon

siehe Beitrag von "fuerza_hercuela" vom 21.05.; siehe Link "Quelle" und "Übersetzungshilfe"

Quelle:

news.prnewswire.com/.../story/05-27-2009/0005032847&EDATE=


Cord Blood America Says Debt Reduced $4.194 Million in 2009

 

SANTA MONICA, Calif., May 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has reduced its secured debt by a total of $4.194 million in the first five months of 2009.


"On April 6th, 2009, Cord Blood America announced it had decreased its debt by $1.75 million this year," said Matthew Schissler, Cord Blood America Founder and CEO. "Since that time, we have further reduced our secured debt by $1.627 million and have eliminated liquidated damages totaling $817,000."


"We have been very forthright with our investors. We have said there are three strong pillars needed to take CBAI to the next level. One is debt reduction, and today's announcement shows our achievement in that sector. The second is organic growth, and our deferred revenues for the first quarter were up 20 percent. The third pillar is acquisitions, and we recently announced Cord Blood America is in the process of building or buying a stem cell laboratory for increased acquisition capacity and higher gross margin," Mr. Schissler said.


"Our strategy for 2009 is in place and we stand by our ability to perform and to make all three pillars strong and sturdy. We urge our shareholders to follow our progress in these important sectors," Cord Blood America's founder said.

doch schonmal der richtige Weg, jetzt schauen wir mal wie sich diese Sache weiterentwickelt

Nasdaq OTC BBHandelsplatz   Letzter   Veränderung   Vortag   letzte Stk.   Tag-Stk.   Kursspanne   Zeit

                                  0,0049 $  +2,08% 0,0048 $ 200.000 20.472.112 0,0047 - 0,0049 21:40:34

www.investorcalendar.com/IC/ClientPage.asp?ID=145176

......legen und abwarten. Denke, da ist was zu holen. Nachdem sie jetzt das Geld für ein eigenes Labor haben.

Meine persönliche Meinung.

habe heute St. 500.00 zu 0,003 EUR gekauft;

12 - 24 Monate liegen lassen, dann staunen!

... mit unter über den Erwarteten Effekt des eigene Labors für Aktionäre und die Zukunft der Firma...

http://www.youtube.com/watch?v=J0IiAUCffSQ

Übrigens wenn sich einer die letzte Quartalsbericht Phonekonferenz angehört hat, da wurde zumindest angedacht das CBAI Expansion in Europa plant. (Primär durch Aufkauf europ. Konkurrenten)

 

 

.....habe schon einige im Depot und warte dann mal ab !

Zwar schon ein paar Tage alt dieser Artikel, aber für Investierte bzw. demnächst Investierte auf diesem Sektor doch sehr interessant. Cord Blood wir davon profitieren. Habe mir mal einige Papierchen von denen ins Depot gelegt und warte mal ab, was da passiert. Bin da sehr positiv eingestellt.

Obama fördert Stammzellenforschung in den USA
09.03.2009

Washington (AFP) — US-Präsident Barack Obama hat eine Kehrtwende in der Stammzellenforschung seines Landes vollzogen. Die Forschung an embryonalen Stammzellen werde in den USA ab sofort wieder mit staatlichen Mitteln unterstützt und vorangetrieben, sagte Obama am Montag in Washington. Der Präsident machte die Bestimmungen seines Vorgängers George W. Bush rückgängig, die den Einsatz von Staatsgeldern stark eingeschränkt hatten.

In der Stammzellenforschung sollten die USA wieder an die Weltspitze rücken, sagte Obama. "Wir eröffnen heute eine neue Front in der Wissenschaft", kündigte er an. Zwar könne er nicht garantieren, ob diese Forschungsrichtung die Hoffnungen auf Durchbrüche bei der Heilung schwerer Krankheiten erfülle. "Ich kann aber versprechen, dass wir es versuchen werden - aktiv, verantwortungsbewusst, und mit der nötigen Dringlichkeit, um verlorenen Boden gutzumachen."

Quelle + Volltext: www.google.com/hostednews/afp/article/...5c-GylVhHxzYnFq1bvM_g

vorgestern eingestiegen,
hoffe die wird sich langsam nach Norden bewegen.


MfG

www.finanznachrichten.de/...tinuing-european-expansion-008.htm

11.06.2009 11:01
Cord Blood America Continuing European Expansion

SANTA MONICA, Calif., June 11 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , one of the largest umbilical cord blood stem cell preservation companies (www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has begun due diligence for sales operation expansion into the European Union, specifically Belgium and Italy.

Cord Blood America's international partner, a.bourkas Co., United, has had operations in Greece since 2006 and has established a sales operation in Germany.

"This is potentially a very profitable new frontier in the stem cell industry and we are pleased to be one of the leaders in this expansion and growth," said founder and CEO Matthew Schissler. "We started small in Europe, and believe now, for a number of fiscal reasons, would be a good time to look at expansion. The value of storing umbilical cord blood stem cells at birth is becoming well known worldwide."

...0.0042 +0.0006 (+16.67%)

........noch ein Grund mehr, hier etwas zu investieren und mal eine Weile abzuwarten. Meine persönliche Meinung!

CBAI: To Continue European Expansion into Belgium and Italy

Cord Blood America, Inc. (CBAI) has begun due diligence for sales operation expansion into the European Union, specifically Belgium and Italy.

Cord Blood America's international partner, a.bourkas Co., United, has had operations in Greece since 2006 and has established a sales operation in Germany.

Quelle + Volltext: www.tradingmarkets.com/.site/news/Stock%20News/2370977/

Übersetzungshilfe: translate.google.de/translate_t#

13 mio buy

3 mio sell

preis konstant bei 0,004$

www.finanznachrichten.de/...uba-with-marketing-partner-008.htm